Research programme: hyperlipidaemia therapies - Handok Inc.Alternative Names: HL 4130
Latest Information Update: 03 Oct 2013
Price : $50
At a glance
- Originator Handok Pharmaceuticals
- Developer Handok Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 03 Oct 2013 Discontinued - Preclinical for Hyperlipidaemia in South Korea (unspecified route)
- 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc.
- 22 Jun 2011 Preclinical trials in Hyperlipidaemia in South Korea (unspecified route)